{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:41:22Z","timestamp":1790775682146,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Abbott"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12325-019-01144-9","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T13:03:00Z","timestamp":1573218180000},"page":"61-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-2923","authenticated-orcid":false,"given":"Giustino","family":"Varrassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Pergolizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Paladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"1144_CR1","unstructured":"Ferry G. Stewart Adams obituary. The Guardian. 2019. https:\/\/www.theguardian.com\/science\/2019\/feb\/13\/stewart-adams-obituary . Accessed 4 Jun 2019."},{"key":"1144_CR2","unstructured":"An interview with Stewart Adams. Cell Press. Trends in Pharmacological Sciences Web site. 2012. https:\/\/www.cell.com\/trends\/pharmacological-sciences\/pdf\/S0165-6147(11)00194-5.pdf . Accessed 4 Jun 2019."},{"issue":"2","key":"1144_CR3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00045391-200007020-00011","volume":"7","author":"LF Prescott","year":"2000","unstructured":"Prescott LF. Paracetamol: past, present, and future. Am J Ther. 2000;7(2):143\u20137.","journal-title":"Am J Ther"},{"key":"1144_CR4","unstructured":"BBC News. Ibupforen: Dr Stewart Adams who helped discover drug dies at 95. BBC. England Web site. 2019. https:\/\/www.bbc.com\/news\/uk-england-nottinghamshire-47073913 . Accessed 4 Jun 2019."},{"key":"1144_CR5","unstructured":"ANSM. [Anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et complications infectieuses graves\u2014Point d\u2019Information]. Agence nationale de securite du medicament et des produits de sante. 2019. https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Anti-inflammatoires-non-steroidiens-AINS-et-complications-infectieuses-graves-Point-d-Information . Accessed 4 Jun 2019."},{"key":"1144_CR6","unstructured":"Taylor N. France\u2019s ANSM warns about NSAIDs following safety review. Regulatory Affairs Professionals. EU Regulatory Roundup Web site. 2019. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2019\/4\/eu-regulatory-roundup-frances-ansm-warns-about-n . Accessed 4 Jun 2019."},{"issue":"9894","key":"1144_CR7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769\u201379.","journal-title":"Lancet"},{"issue":"4","key":"1144_CR8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","volume":"82","author":"C Patrono","year":"2016","unstructured":"Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol. 2016;82(4):957\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"1144_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-90305-7_43-1","volume-title":"Brain and heart dynamics","author":"G Varrassi","year":"2019","unstructured":"Varrassi G, Pergolizzi J, Peppin J, Paladini A. Analgesic drugs and cardiac safety. In: S. Govoni et al, editors. Brain and Heart Dynamics. Switzerland. Springer; 2019. https:\/\/doi.org\/10.1007\/978-3-319-90305-7_43-1 ."},{"issue":"4 Suppl","key":"1144_CR10","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.semarthrit.2015.11.009","volume":"45","author":"JP Pelletier","year":"2016","unstructured":"Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S22\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1144_CR11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0002-9343(84)80017-0","volume":"77","author":"KS Albert","year":"1984","unstructured":"Albert KS, Gernaat CM. Pharmacokinetics of ibuprofen. Am J Med. 1984;77(1):40\u20136.","journal-title":"Am J Med"},{"key":"1144_CR12","unstructured":"Bratty J, Rotherham N, Underwood L. Comparative bioavailability of ibuprofen from two Brufen Retard tablets 80\u00a0mg as a single dose and from Brufen immediate release tablets 400\u00a0mg taken four times a day. In: Maddison P, ed. New developments in the management of chronic arthritis. Highlights of an international symposium Held in Rome, Italy. vol 41. Theale, Berkshire, United Kingdom: Colwood House Medical Publications (UK) Ltd.; 1991."},{"issue":"11","key":"1144_CR13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0011-393X(05)80313-3","volume":"55","author":"M Driessens","year":"1994","unstructured":"Driessens M, Famaey J-P, Orloff S, et al. Efficacy and tolerability of sustained-release ibuprofen in the treatment of patients with chronic back pain. Curr Ther Research. 1994;55(11):1283\u201392.","journal-title":"Curr Ther Research."},{"issue":"1","key":"1144_CR14","first-page":"10","volume":"47","author":"T O\u2019Connor","year":"1993","unstructured":"O\u2019Connor T, Anderson A, Lennox B, Muldoon C. A novel sustained-release formulation of ibuprofen provides effective once-daily therapy in the treatment of rheumatoid arthritis and osteoarthritis. Brit J Clin Pharmacol. 1993;47(1):10\u20133.","journal-title":"Brit J Clin Pharmacol."},{"issue":"11","key":"1144_CR15","first-page":"1061","volume":"15","author":"N Moore","year":"2015","unstructured":"Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug\u2013drug interactions with over-the-counter NSAIDs. Ther Clin Risk Managem. 2015;15(11):1061\u201375.","journal-title":"Ther Clin Risk Managem."},{"issue":"2","key":"1144_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00044011-199918020-00001","volume":"18","author":"N Moore","year":"1999","unstructured":"Moore N, Van Ganse E, Le Parc JM, et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerabiity study. Clin Drug Investig. 1999;18(2):89\u201398.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1144_CR17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cpt.696","volume":"102","author":"C Patrono","year":"2017","unstructured":"Patrono C, Baigent C. Coxibs, traditional NSAIDs, and cardiovascular safety post-precision: what we thought we knew then and what we think we know now. Clin Pharmacol Ther. 2017;102(2):238\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"26","key":"1144_CR18","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"1144_CR19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","volume":"130","author":"DH Solomon","year":"2017","unstructured":"Solomon DH, Husni ME, Libby PA, et al. The risk of major nsaid toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the precision trial. Am J Med. 2017;130(12):1415\u20131422.e1414.","journal-title":"Am J Med"},{"issue":"11","key":"1144_CR20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092\u2013102.","journal-title":"N Engl J Med"},{"issue":"8","key":"1144_CR21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1503\/cmaj.1041606","volume":"171","author":"B Sibbald","year":"2004","unstructured":"Sibbald B. Rofecoxib (Vioxx) voluntriy withdrawn from market. Can Med Assoc J. 2004;171(8):1027\u20138.","journal-title":"Can Med Assoc J"},{"key":"1144_CR22","unstructured":"FDA. C\u039f\u03a7-2 selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs. Food and Drug Administration. Drug Safety and Availability Web site. 2005. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/cox-2-selective-includes-bextra-celebrex-and-vioxx-and-non-selective-non-steroidal-anti-inflammatory . Accessed 11 Jun 2019."},{"key":"1144_CR23","unstructured":"FDA. FDA Drug Safety Communication: FDA strenghtens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Food and Drug Administration. Drug Safety and Availability Web site. 2015. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory . Accessed 11 Jun 2019."},{"issue":"5","key":"1144_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40256-017-0223-6","volume":"17","author":"D Thomas","year":"2017","unstructured":"Thomas D, Ali Z, Zachariah S, Sundararaj KGS, Van Cuyk M, Cooper JC. Coxibs refocus attention on the cardiovascular risks of non-aspirin NSAIDs. Am J Cardiovasc Drugs. 2017;17(5):343\u20136.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"10","key":"1144_CR25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/jphp.12770","volume":"69","author":"A Moore","year":"2017","unstructured":"Moore A, Crossley A, Ng B, Phillips L, Sancak O, Rainsford KD. Use of multicriteria decision analysis for assessing the benefit and risk of over-the-counter analgesics. J Pharm Pharmacol. 2017;69(10):1364\u201373.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"1144_CR26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/009127009903900513","volume":"39","author":"DE Kellstein","year":"1999","unstructured":"Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol. 1999;39(5):520\u201332.","journal-title":"J Clin Pharmacol"},{"key":"1144_CR27","first-page":"28","volume":"135","author":"N Moore","year":"2003","unstructured":"Moore N. Forty years of ibuprofen use. Int J Clin Pract Suppl. 2003;135:28\u201331.","journal-title":"Int J Clin Pract Suppl"},{"key":"1144_CR28","first-page":"CD010794","volume":"11","author":"RA Moore","year":"2015","unstructured":"Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. Non-prescription (OTC) oral analgesics for acute pain\u2014an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;11:CD010794.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1144_CR29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0006-2952(00)00576-1","volume":"61","author":"LM Lichtenberger","year":"2001","unstructured":"Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol. 2001;61(6):631\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1144_CR30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/gut.41.3.344","volume":"41","author":"S Somasundaram","year":"1997","unstructured":"Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the \u201ctopical\u201d phase of NSAID induced injury to the rat intestine. Gut. 1997;41(3):344\u201353.","journal-title":"Gut"},{"issue":"4","key":"1144_CR31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365529509093280","volume":"30","author":"S Somasundaram","year":"1995","unstructured":"Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol. 1995;30(4):289\u201399.","journal-title":"Scand J Gastroenterol"},{"issue":"135","key":"1144_CR32","first-page":"43","volume":"2003","author":"D Henry","year":"2003","unstructured":"Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl. 2003;2003(135):43\u20139.","journal-title":"Int J Clin Pract Suppl."},{"issue":"3","key":"1144_CR33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/ar146","volume":"2001","author":"LA Garcia Rodriguez","year":"2001","unstructured":"Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;2001(3):98\u2013101.","journal-title":"Arthritis Res."},{"issue":"12","key":"1144_CR34","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/BF03261999","volume":"35","author":"J Castellsague","year":"2012","unstructured":"Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127\u201346.","journal-title":"Drug Saf"},{"key":"1144_CR35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ijcp.12048","volume":"178","author":"I Bjarnason","year":"2013","unstructured":"Bjarnason I. Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract Suppl. 2013;178:37\u201342.","journal-title":"Int J Clin Pract Suppl."},{"issue":"2","key":"1144_CR36","first-page":"137","volume":"5","author":"WJ Blot","year":"2000","unstructured":"Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137\u201342.","journal-title":"J Epidemiol Biostat."},{"issue":"6","key":"1144_CR37","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2005.08.051","volume":"129","author":"JD Lewis","year":"2005","unstructured":"Lewis JD, Kimmel SE, Localio AR, et al. Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 2005;129(6):1865\u201374.","journal-title":"Gastroenterology"},{"issue":"7046","key":"1144_CR38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","volume":"312","author":"D Henry","year":"1996","unstructured":"Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ (Clin Res Ed). 1996;312(7046):1563\u20136.","journal-title":"BMJ (Clin Res Ed)."},{"issue":"3","key":"1144_CR39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2125.2002.01636.x","volume":"54","author":"SC Lewis","year":"2002","unstructured":"Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1144_CR40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/ard.2003.015925","volume":"63","author":"F Richy","year":"2004","unstructured":"Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63(7):759\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1144_CR41","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2014.06.007","volume":"147","author":"GM Masclee","year":"2014","unstructured":"Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784\u2013792.e789 (quiz e713\u2013784).","journal-title":"Gastroenterology"},{"key":"1144_CR42","first-page":"43","volume":"135","author":"D Henry","year":"2003","unstructured":"Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl. 2003;135:43\u20139.","journal-title":"Int J Clin Pract Suppl."},{"issue":"7","key":"1144_CR43","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2036.1999.00539.x","volume":"13","author":"G Doyle","year":"1999","unstructured":"Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther. 1999;13(7):897\u2013906.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1144_CR44","first-page":"2226","volume":"30","author":"JF Fries","year":"2003","unstructured":"Fries JF, Bruce B. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2003;30(10):2226\u201333.","journal-title":"J Rheumatol"},{"issue":"1","key":"1144_CR45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s100670200007","volume":"21","author":"JM Le Parc","year":"2002","unstructured":"Le Parc JM, Van Ganse E, Moore N, Wall R, Schneid H, Verriere F. Comparative tolerability of paracetamol, aspirin and ibuprofen for short-term analgesia in patients with musculoskeletal conditions: results in 4291 patients. Clin Rheumatol. 2002;21(1):28\u201331.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"1144_CR46","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/apt.14610","volume":"47","author":"ND Yeomans","year":"2018","unstructured":"Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018;47(11):1453\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1144_CR47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1185\/03007995.2011.633990","volume":"28","author":"SL Michels","year":"2012","unstructured":"Michels SL, Collins J, Reynolds MW, Abramsky S, Paredes-Diaz A, McCarberg B. Over-the-counter ibuprofen and risk of gastrointestinal bleeding complications: a systematic literature review. Curr Med Res Opin. 2012;28(1):89\u201399.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1144_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/J354v20n03_03","volume":"20","author":"JE Biskupiak","year":"2006","unstructured":"Biskupiak JE, Brixner DI, Howard K, Oderda GM. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliative Care Pharmacother. 2006;20(3):7\u201314.","journal-title":"J Pain Palliative Care Pharmacother"},{"issue":"9","key":"1144_CR49","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/ard.2003.011403","volume":"63","author":"F Boureau","year":"2004","unstructured":"Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63(9):1028\u201334.","journal-title":"Ann Rheum Dis."},{"key":"1144_CR50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.phrs.2015.12.026","volume":"104","author":"C Rafaniello","year":"2016","unstructured":"Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: results of a pharmacovigilance reporting system. Pharmacol Res. 2016;104:108\u201314.","journal-title":"Pharmacol Res"},{"issue":"5","key":"1144_CR51","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/ard.2007.087254","volume":"68","author":"MW van der Linden","year":"2009","unstructured":"van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68(5):668\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1144_CR52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/ejhpharm-2016-001087","volume":"24","author":"JL Marco Garbayo","year":"2017","unstructured":"Marco Garbayo JL, Koninckx Canada M, Perez Castello I, Faus Soler MT, Fuster Torres R, Moncho Escriva M. Cross-sectional analysis of retrospective case series of hospitalisations for gastropathy caused by non-steroidal anti-inflammatory treatment: risk factors and gastroprotection use. Eur J Hosp Pharm Sci Pract. 2017;24(6):355\u201360.","journal-title":"Eur J Hosp Pharm Sci Pract."},{"issue":"3","key":"1144_CR53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/00913847.2015.1066229","volume":"43","author":"AE Bello","year":"2015","unstructured":"Bello AE, Kent JD, Holt RJ. Gastroprotective efficacy and safety of single-tablet ibuprofen\/famotidine vs ibuprofen in older persons. Phys Sportsmed. 2015;43(3):193\u20139.","journal-title":"Phys Sportsmed."},{"issue":"4","key":"1144_CR54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3810\/pgm.2014.07.2786","volume":"126","author":"AE Bello","year":"2014","unstructured":"Bello AE, Kent JD, Grahn AY, Rice P, Holt RJ. Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen\/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. Postgrad Med. 2014;126(4):82\u201391.","journal-title":"Postgrad Med"},{"issue":"3","key":"1144_CR55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1185\/03007995.2014.1000086","volume":"31","author":"AE Bello","year":"2015","unstructured":"Bello AE, Grahn AY, Ball J, Kent JD, Holt RJ. One-year safety of ibuprofen\/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. Curr Med Res Opin. 2015;31(3):407\u201320.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1144_CR56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ajg.2011.443","volume":"107","author":"L Laine","year":"2012","unstructured":"Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-blind randomized trials of single-tablet ibuprofen\/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012;107(3):379\u201386.","journal-title":"Am J Gastroenterol."},{"issue":"8900","key":"1144_CR57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","volume":"343","author":"LA Garcia Rodriguez","year":"1994","unstructured":"Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet (Lond Engl). 1994;343(8900):769\u201372.","journal-title":"Lancet (Lond Engl)."},{"issue":"1","key":"1144_CR58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.gastro.2007.04.045","volume":"133","author":"CJ Hawkey","year":"2007","unstructured":"Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology. 2007;133(1):57\u201364.","journal-title":"Gastroenterology"},{"issue":"2","key":"1144_CR59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1517\/14740338.2014.846324","volume":"13","author":"N Moore","year":"2014","unstructured":"Moore N, Salvo F, Duong M, Blin P, Pariente A. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf. 2014;13(2):167\u201379.","journal-title":"Expert Opin Drug Saf."},{"issue":"2","key":"1144_CR60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinternmed.2008.525","volume":"169","author":"GH Gislason","year":"2009","unstructured":"Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141\u20139.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1144_CR61","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/art.21887","volume":"54","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006;54(5):1378\u201389.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1144_CR62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","volume":"85","author":"EL Fosbol","year":"2009","unstructured":"Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1144_CR63","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bcpt.13182","volume":"124","author":"CA Barcella","year":"2019","unstructured":"Barcella CA, Lamberts M, McGettigan P, et al. Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy\u2014a nationwide study in patients with osteoarthritis. Basic Clin Pharmacol Toxicol. 2019;124(5):629\u201341.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"1144_CR64","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/clc.22814","volume":"40","author":"CJ Pepine","year":"2017","unstructured":"Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view. Clin Cardiol. 2017;40(12):1352\u20136.","journal-title":"Clin Cardiol"},{"issue":"8","key":"1144_CR65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1751-7176.2008.07802.x","volume":"10","author":"ME Farkouh","year":"2008","unstructured":"Farkouh ME, Verheugt FW, Ruland S, et al. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen. J Clin Hypertens (Greenwich). 2008;10(8):592\u2013602.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"44","key":"1144_CR66","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","volume":"38","author":"F Ruschitzka","year":"2017","unstructured":"Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen ambulatory blood pressure measurement) trial. Eur Heart J. 2017;38(44):3282\u201392.","journal-title":"Eur Heart J"},{"issue":"4","key":"1144_CR67","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/STROKEAHA.115.012091","volume":"47","author":"J Gonzalez-Valcarcel","year":"2016","unstructured":"Gonzalez-Valcarcel J, Sissani L, Labreuche J, et al. Paracetamol, ibuprofen, and recurrent major cardiovascular and major bleeding events in 19,120 patients with recent ischemic stroke. Stroke. 2016;47(4):1045\u201352.","journal-title":"Stroke"},{"key":"1144_CR68","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (Clin Res Ed). 2011;342:c7086.","journal-title":"BMJ (Clin Res Ed)."},{"issue":"3","key":"1144_CR69","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00045391-200405000-00002","volume":"11","author":"L Lipworth","year":"2004","unstructured":"Lipworth L, Friis S, Blot WJ, et al. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther. 2004;11(3):156\u201363.","journal-title":"Am J Ther"},{"issue":"11","key":"1144_CR70","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-018-0686-7","volume":"41","author":"M Duong","year":"2018","unstructured":"Duong M, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N. Coronary events after dispensing of ibuprofen: a propensity score-matched cohort study versus paracetamol in the French nationwide claims database sample. Drug Saf. 2018;41(11):1049\u201358.","journal-title":"Drug Saf"},{"issue":"5","key":"1144_CR71","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bcp.13537","volume":"84","author":"YH Dong","year":"2018","unstructured":"Dong YH, Chang CH, Wu LC, Hwang JS, Toh S. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. Br J Clin Pharmacol. 2018;84(5):1045\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1144_CR72","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.ki.5001766","volume":"70","author":"A Whelton","year":"2006","unstructured":"Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70(8):1495\u2013502.","journal-title":"Kidney Int"},{"issue":"5","key":"1144_CR73","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1186\/ar2047","volume":"8","author":"G Singh","year":"2006","unstructured":"Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther. 2006;8(5):R153.","journal-title":"Arthritis Res Ther."},{"issue":"20","key":"1144_CR74","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/CIRCULATIONAHA.110.004671","volume":"123","author":"AM Schjerning Olsen","year":"2011","unstructured":"Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226\u201335.","journal-title":"Circulation"},{"issue":"25","key":"1144_CR75","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","volume":"113","author":"GH Gislason","year":"2006","unstructured":"Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906\u201313.","journal-title":"Circulation"},{"issue":"8","key":"1144_CR76","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/archinte.164.8.852","volume":"164","author":"TN Patel","year":"2004","unstructured":"Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med. 2004;164(8):852\u20136.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1144_CR77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semerg.2017.07.004","volume":"44","author":"L Munoz Olmo","year":"2018","unstructured":"Munoz Olmo L, Juan Armas J, Gomariz Garcia JJ. Risk of fatal\/non-fatal events in patients with previous coronary heart disease\/acute myocardial infarction and treatment with non-steroidal anti-inflammatory drugs. Semergen. 2018;44(5):355\u201363.","journal-title":"Semergen."},{"issue":"11","key":"1144_CR78","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.clinthera.2006.11.009","volume":"28","author":"WF Huang","year":"2006","unstructured":"Huang WF, Hsiao FY, Wen YW, Tsai YW. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Clin Ther. 2006;28(11):1827\u201336.","journal-title":"Clin Ther"},{"issue":"11","key":"1144_CR79","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/17512433.2016.1230495","volume":"9","author":"G Zingler","year":"2016","unstructured":"Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol. 2016;9(11):1479\u201392.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"1144_CR80","first-page":"349","volume":"78","author":"GR Prozzi","year":"2018","unstructured":"Prozzi GR, Canas M, Urtasun MA, Buschiazzo HO, Dorati CM, Mordujovich-Buschiazzo P. Cardiovascular risk of non-steroidal anti-inflammatory drugs. Med (B Aires). 2018;78(5):349\u201355.","journal-title":"Med (B Aires)."},{"key":"1144_CR81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.1993.293","volume":"44","author":"D Schlondorff","year":"1993","unstructured":"Schlondorff D. Renal compliations of nonsteroidal anti-inflammatory drugs. Kidney Internat. 1993;44:643\u201353.","journal-title":"Kidney Internat."},{"issue":"Suppl 1","key":"1144_CR82","first-page":"Si53","volume":"69","author":"MR Weir","year":"2002","unstructured":"Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(Suppl 1):Si53\u20138.","journal-title":"Cleve Clin J Med."},{"key":"1144_CR83","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","volume":"106","author":"A Whelton","year":"1999","unstructured":"Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13S\u201324S.","journal-title":"Am J Med"},{"issue":"63","key":"1144_CR84","first-page":"2227","volume":"2015","author":"American Geriatric Society, Panel. BCUE","year":"2015","unstructured":"American Geriatric Society, Panel. BCUE. American Geriatrics Society 2015 updated Beers croiteria for potentially inappropriate drug use in older adults. J Am Geriatr Soc. 2015;2015(63):2227\u201346.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"1144_CR85","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1152\/jappl.1999.86.2.598","volume":"86","author":"WB Farquhar","year":"1999","unstructured":"Farquhar WB, Morgan AL, Zambraski EJ, Kenney WL. Effects of acetaminophen and ibuprofen on renal function in the stressed kidney. J Appl Physiol (1985). 1999;86(2):598\u2013604.","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"1144_CR86","doi-asserted-by":"crossref","first-page":"230949901880866","DOI":"10.1177\/2309499018808669","volume":"26","author":"O Aweid","year":"2018","unstructured":"Aweid O, Haider Z, Saed A, Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: a systematic review of safety. J Orthopaedic Surg (Hong Kong). 2018;26(3):2309499018808669.","journal-title":"J Orthopaedic Surg (Hong Kong)."},{"issue":"5","key":"1144_CR87","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a010234","volume":"151","author":"MR Griffin","year":"2000","unstructured":"Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488\u201396.","journal-title":"Am J Epidemiol"},{"issue":"7405","key":"1144_CR88","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.327.7405.18","volume":"327","author":"G Traversa","year":"2003","unstructured":"Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ (Clin Res Ed). 2003;327(7405):18\u201322.","journal-title":"BMJ (Clin Res Ed)."},{"issue":"45","key":"1144_CR89","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.3748\/wjg.v16.i45.5651","volume":"16","author":"F Bessone","year":"2010","unstructured":"Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16(45):5651\u201361.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1144_CR90","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1542-3565(04)00777-3","volume":"3","author":"A Rostom","year":"2005","unstructured":"Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol. 2005;3(5):489\u201398.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1144_CR91","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bcp.12938","volume":"82","author":"M Donati","year":"2016","unstructured":"Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case\u2013control study in Italy. Br J Clin Pharmacol. 2016;82(1):238\u201348.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1144_CR92","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/pds.4640","volume":"27","author":"SE Gulmez","year":"2018","unstructured":"Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Saf. 2018;27(11):1174\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1144_CR93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40264-012-0013-7","volume":"36","author":"SE Gulmez","year":"2013","unstructured":"Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135\u201344.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"1144_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2012.03766.x","volume":"18","author":"C Pelucchi","year":"2012","unstructured":"Pelucchi C, Grigoryan L, Galeone C, et al. Guideline for the management of acute sore throat. Clin Microbiol Infect. 2012;18(Suppl 1):1\u201328.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"1144_CR95","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1542\/peds.107.5.1108","volume":"107","author":"SM Lesko","year":"2001","unstructured":"Lesko SM, O\u2019Brien KL, Schwartz B, Vezina R, Mitchell AA. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001;107(5):1108\u201315.","journal-title":"Pediatrics"},{"issue":"9","key":"1144_CR96","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/infdis\/jit594","volume":"209","author":"SM Hamilton","year":"2014","unstructured":"Hamilton SM, Bayer CR, Stevens DL, Bryant AE. Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis. J Infect Dis. 2014;209(9):1429\u201335.","journal-title":"J Infect Dis"},{"issue":"4","key":"1144_CR97","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/clinids\/21.4.977","volume":"21","author":"DL Stevens","year":"1995","unstructured":"Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis. 1995;21(4):977\u201380.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1144_CR98","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1469-0691.2002.00396.x","volume":"8","author":"MR Barnham","year":"2002","unstructured":"Barnham MR, Weightman NC, Anderson AW, Tanna A. Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin Microbiol Infect. 2002;8(3):174\u201381.","journal-title":"Clin Microbiol Infect."},{"issue":"4 Pt 1","key":"1144_CR99","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1542\/peds.103.4.783","volume":"103","author":"DM Zerr","year":"1999","unstructured":"Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE. A case\u2013control study of necrotizing fasciitis during primary varicella. Pediatrics. 1999;103(4 Pt 1):783\u201390.","journal-title":"Pediatrics"},{"issue":"4","key":"1144_CR100","first-page":"225","volume":"82","author":"DM Aronoff","year":"2003","unstructured":"Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore). 2003;82(4):225\u201335.","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"1144_CR101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3201\/eid1402.070888","volume":"14","author":"TL Lamagni","year":"2008","unstructured":"Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003\u20132004. Emerg Infect Dis. 2008;14(2):202\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"1144_CR102","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1742-1241.2002.tb11366.x","volume":"56","author":"N Moore","year":"2002","unstructured":"Moore N, Le Parc JM, van Ganse E, Wall R, Schneid H, Cairns R. Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. Int J Clin Pract. 2002;56(10):732\u20134.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"1144_CR103","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2710.2006.00754.x","volume":"31","author":"R Eccles","year":"2006","unstructured":"Eccles R. Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. J Clin Pharm Ther. 2006;31(4):309\u201319.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"1144_CR104","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1086\/593016","volume":"198","author":"SM Hamilton","year":"2008","unstructured":"Hamilton SM, Bayer CR, Stevens DL, Lieber RL, Bryant AE. Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection. J Infect Dis. 2008;198(11):1692\u20138.","journal-title":"J Infect Dis"},{"issue":"6","key":"1144_CR105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmii.2011.04.012","volume":"44","author":"TC Weng","year":"2011","unstructured":"Weng TC, Chen CC, Toh HS, Tang HJ. Ibuprofen worsens Streptococcus pyogenes soft tissue infections in mice. J Microbiol Immunol Infect. 2011;44(6):418\u201323.","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"1144_CR106","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1203\/01.PDR.0000242258.52590.b5","volume":"60","author":"G del Prado","year":"2006","unstructured":"del Prado G, Martinez-Marin C, Huelves L, et al. Impact of ibuprofen therapy in the outcome of experimental pneumococcal acute otitis media treated with amoxicillin or erythromycin. Pediatr Res. 2006;60(5):555\u20139.","journal-title":"Pediatr Res"},{"key":"1144_CR107","first-page":"CD001505","volume":"6","author":"LC Lands","year":"2013","unstructured":"Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2013;6:CD001505.","journal-title":"Cochrane Database Syst Rev."},{"key":"1144_CR108","first-page":"3","volume":"62","author":"PN Shah","year":"2018","unstructured":"Shah PN, Marshall-Batty KR, Smolen JA, et al. Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens. Antimicrob Agents Chemother. 2018;62:3.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"1144_CR109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MCP.0b013e32831311e8","volume":"14","author":"MW Konstan","year":"2008","unstructured":"Konstan MW. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med. 2008;14(6):567\u201373.","journal-title":"Curr Opin Pulm Med."},{"issue":"4","key":"1144_CR110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4103\/ijmy.ijmy_142_18","volume":"7","author":"ZI Kirkwood","year":"2018","unstructured":"Kirkwood ZI, Millar BC, Downey DG, Moore JE. Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus. Int J Mycobacteriol. 2018;7(4):358\u201360.","journal-title":"Int J Mycobacteriol."},{"issue":"2","key":"1144_CR111","first-page":"118","volume":"67","author":"DO Sordelli","year":"1985","unstructured":"Sordelli DO, Cerquetti MC, el-Tawil G, Ramwell PW, Hooke AM, Bellanti JA. Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa. Eur J Respir Dis. 1985;67(2):118\u201327.","journal-title":"Eur J Respir Dis."},{"issue":"4","key":"1144_CR112","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/PRS.0000000000002027","volume":"137","author":"BP Kelley","year":"2016","unstructured":"Kelley BP, Bennett KG, Chung KC, Kozlow JH. Ibuprofen may not increase bleeding risk in plastic surgery: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137(4):1309\u201316.","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"1144_CR113","first-page":"363","volume":"22","author":"I Dona","year":"2012","unstructured":"Dona I, Blanca-Lopez N, Torres MJ, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22(5):363\u201371.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"1144_CR114","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaip.2014.03.014","volume":"2","author":"MV Aun","year":"2014","unstructured":"Aun MV, Blanca M, Garro LS, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol Pract. 2014;2(4):414\u201320.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"3","key":"1144_CR115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.iac.2014.04.001","volume":"34","author":"MJ Torres","year":"2014","unstructured":"Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am. 2014;34(3):507\u201324.","journal-title":"Immunol Allergy Clin North Am."},{"issue":"12","key":"1144_CR116","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0895-4356(01)00392-4","volume":"54","author":"AD McMahon","year":"2001","unstructured":"McMahon AD, Evans JMM, MacDonald TM. Hypersensitivity reactions associated with exposure to naproxen and ibuprofen: a cohort study. J Clin Epidemiol. 2001;54(12):1271\u20134.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1144_CR117","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.trsl.2010.01.005","volume":"155","author":"RM Nanau","year":"2010","unstructured":"Nanau RM, Neuman MG. Ibuprofen-induced hypersensitivity syndrome. Transl Res. 2010;155(6):275\u201393.","journal-title":"Transl Res."},{"issue":"4","key":"1144_CR118","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1073\/pnas.1715035115","volume":"115","author":"DM Kristensen","year":"2018","unstructured":"Kristensen DM, Desdoits-Lethimonier C, Mackey AL, et al. Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism. Proc Natl Acad Sci USA. 2018;115(4):E715\u2013e724.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1144_CR119","doi-asserted-by":"crossref","first-page":"44184","DOI":"10.1038\/srep44184","volume":"7","author":"M Ben Maamar","year":"2017","unstructured":"Ben Maamar M, Lesne L, Hennig K, et al. Ibuprofen results in alterations of human fetal testis development. Sci Rep. 2017;7:44184.","journal-title":"Sci Rep"},{"issue":"8","key":"1144_CR120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/cbin.10959","volume":"42","author":"H Akrami","year":"2018","unstructured":"Akrami H, Moradi B, Borzabadi Farahani D, Mehdizadeh K. Ibuprofen reduces cell proliferation through inhibiting Wnt\/beta catenin signaling pathway in gastric cancer stem cells. Cell Biol Int. 2018;42(8):949\u201358.","journal-title":"Cell Biol Int"},{"issue":"5","key":"1144_CR121","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1007\/s13277-014-2952-3","volume":"36","author":"H Akrami","year":"2015","unstructured":"Akrami H, Aminzadeh S, Fallahi H. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015;36(5):3237\u201343.","journal-title":"Tumour Biol"},{"key":"1144_CR122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mrgentox.2017.12.001","volume":"826","author":"O Dandah","year":"2018","unstructured":"Dandah O, Najafzadeh M, Isreb M, et al. Aspirin and ibuprofen, in bulk and nanoforms: effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals. Mutat Res Genet Toxicol Environ Mutagen. 2018;826:41\u20136.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"2","key":"1144_CR123","doi-asserted-by":"crossref","first-page":"e023715","DOI":"10.1136\/bmjopen-2018-023715","volume":"9","author":"C Gay-Escoda","year":"2019","unstructured":"Gay-Escoda C, Hanna M, Montero Matamala A, et al. Tramadol\/dexketoprofen (TRAM\/DKP) compared with tramadol\/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study). BMJ Open. 2019;9(2):e023715.","journal-title":"BMJ Open."},{"issue":"5","key":"1144_CR124","first-page":"E863","volume":"18","author":"A Paladini","year":"2015","unstructured":"Paladini A, Fusco M, Coaccioli S, Skaper SD, Varrassi G. Chronic pain in the elderly: the case for new therapeutic strategies. Pain Physician. 2015;18(5):E863\u201376.","journal-title":"Pain Physician."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01144-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01144-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01144-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T14:39:50Z","timestamp":1695393590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01144-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01144-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"2 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}